Abbott Laboratories (ABT.N)
20 Apr 2018
Wed, Apr 18 2018
Abbott Laboratories' just beat expectations for first quarter profits and revenue on Wednesday but stuck to a full-year profit forecast some investors had expected would be raised, sending the healthcare company's shares lower.
* Analysts cite disappointment on whisper numbers among investors
* Q1 GAAP EARNINGS PER SHARE $0.23 FROM CONTINUING OPERATIONS
April 18 Abbott Laboratories on Wednesday posted a 16.7 percent rise in quarterly revenue, helped by strong demand for its newer devices.
BRIEF-Abbott Initiates Groundbreaking Study To Assess Superiority Of High-Resolution Imaging Versus Standard-Of Care Angiography In Treating Coronary Artery Disease
* RESOLUTION IMAGING RESULT IN LARGER VESSEL DIAMETERS Source text for Eikon: Further company coverage:
* ABBOTT INITIATES TRIAL TO EVALUATE IMPROVED SURVIVAL AND OUTCOMES WITH THE CARDIOMEMS MONITOR
BOSTON, March 23 Alere Inc has agreed to pay $33.2 million to resolve claims it knowingly sold unreliable diagnostic testing devices to hospitals prior to its acquisition by Abbott Laboratories last year, the U.S. Justice Department said on Friday.
BRIEF-Abbott's MitraClip Therapy Receives National Reimbursement In Japan To Treat Patients With Mitral Regurgitation
* ABBOTT'S MITRACLIP THERAPY RECEIVES NATIONAL REIMBURSEMENT IN JAPAN TO TREAT PATIENTS WITH MITRAL REGURGITATION
BRIEF-Abbott Laboratories CEO Miles White's Total Compensation,Without Change In Pension Value Was $16.8 Mln V/s $17.4 Million In 2016
* ABBOTT LABORATORIES CEO MILES D. WHITE'S 2017 TOTAL COMPENSATION(TOTAL WITHOUT CHANGE IN PENSION VALUE) WAS $16.8 MILLION VERSUS $17.4 MILLION IN 2016 – SEC FILING Source text (http://bit.ly/2IwpJvl) Further company coverage: (Reuters.Brief@thomsonreuters.com)
A federal judge on Friday allowed Abbott Laboratories to question a wholesaler and its former lawyer about why they withheld documents sought by the healthcare giant in a trademark infringement case, saying there is probable cause to believe they engaged in discovery fraud.
- The Passive DGI Core Portfolio: Income, Safety, And Growth
- Danaher's Growing Leverage To Life Sciences Improves The Long-Term Outlook
- Abbott Laboratories 2018 Q1 - Results - Earnings Call Slides
- Abbott Laboratories' (ABT) CEO Miles White on Q1 2018 Results - Earnings Call Transcript
- Taiwan Liposome Company Files Terms For U.S. IPO
- Baby DivHut Dividend Income Portfolio Update Q1 2018